by dyadic | Mar 30, 2021 | Press Releases
Advancing Dyadic’s proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial To validate C1 produced proteins are safe in humans and accelerate C1 adoption and commercialization To serve as proof of concept for...
by dyadic | Mar 29, 2021 | Press Releases
Advancing Dyadic’s proprietary owned COVID-19 vaccine candidate, DYAI-100, towards first-in-human Phase 1 clinical trialEngaged CR2O, a contract research organization, to manage and support further pre-clinical and clinical developmentTo validate C1 produced...
by dyadic | Mar 22, 2021 | Press Releases
Expanding existing COVID-19 vaccine research collaboration which began in July 2020.Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two or more of the current and future COVID-19 variants (e.g.,...
by dyadic | Mar 18, 2021 | Press Releases
Israel Institute for Biological Research (IIBR) reports successful challenge studies using human ACE2 transgenic mice vaccinated with SARS-CoV-2-S-RBD vaccine candidate manufactured from C1-cellsDYAI-100 generated high levels of neutralizing antibodies in preclinical...
by dyadic | Mar 16, 2021 | Press Releases
JUPITER, FL / ACCESSWIRE / March 16, 2021 / Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and...
by dyadic | Mar 9, 2021 | Press Releases
Results demonstrate that Dyadic’s C1 platform produced record levels of safe and effective vaccines in animal trials and further positions C1 products for potential human clinical trialsJUPITER, Fla., March 09, 2021 (GLOBE NEWSWIRE) — Dyadic International,...
